Statute Details
- Title: Health Products (Exemptions) Order 2016
- Act Code: HPA2007-S536-2016
- Legislative Type: Subsidiary legislation (SL)
- Authorising Act: Health Products Act (Cap. 122D)
- Power Used: Section 70 of the Health Products Act
- Enacting Authority: Health Sciences Authority (HSA)
- Commencement: 1 November 2016
- Current Version: Current version as at 27 Mar 2026
- Key Provisions: Section 2 (definitions); Section 3 (exemptions by product category); Section 4 (revocation)
- Schedules: First Schedule (therapeutic products); Second Schedule (medical devices); Third Schedule (CTGT products)
- Notable Amendments (timeline): Amended by S 321/2018; S 110/2021 (effective 1 Mar 2021); S 435/2023; S 804/2023
What Is This Legislation About?
The Health Products (Exemptions) Order 2016 (“Exemptions Order”) is a Singapore subsidiary legislation made under the Health Products Act (Cap. 122D). In plain terms, it creates exemptions from certain regulatory requirements under the Health Products regulatory framework for specific categories of health products.
The Order is not a standalone regulatory regime. Instead, it operates as a “gatekeeper” document: it identifies which therapeutic products, medical devices, and (since amendments effective 1 March 2021) cell, tissue and gene therapy (CTGT) products are exempt from specified provisions of the Health Products Act and/or related regulations. For practitioners, the practical value lies in mapping a product’s category to the relevant schedule and then determining what regulatory obligations are removed or modified.
Because the Order is structured around product categories, it is particularly relevant to licensing, compliance, and enforcement questions. For example, a manufacturer, importer, or sponsor may need to know whether a product must be registered, whether licensing requirements apply, and whether certain controls (such as requirements relating to therapeutic claims, quality and safety oversight, or device-related obligations) are triggered. The Exemptions Order provides the legal basis for “not having to comply” with specified requirements—subject to the precise conditions and scope stated in the schedules.
What Are the Key Provisions?
Section 1 (Citation and commencement) sets the legal identity and start date of the Order. It provides that the Exemptions Order is the “Health Products (Exemptions) Order 2016” and comes into operation on 1 November 2016. This matters for determining which version applies to conduct (e.g., applications, importation, or marketing) occurring before and after commencement.
Section 2 (Definitions) supplies the key interpretive terms used throughout the Order. The definitions are anchored to the Health Products Act’s product categorisation framework. In particular, the Order defines:
- “therapeutic product” as a health product categorised as such in the First Schedule to the Act;
- “medical device” as a health product categorised as such in the First Schedule to the Act;
- “CTGT product” as a health product categorised as a cell, tissue or gene therapy product in the First Schedule to the Act (with an amendment effective 1 March 2021); and
- Regulatory instruments referenced for CTGT and therapeutic products: the CTGT Products Regulations 2021 and the Therapeutic Products Regulations 2016.
These definitions are crucial because exemptions are category-specific. A product that is misclassified may lead to incorrect reliance on an exemption.
Section 3 (Exemptions) is the core operative provision. It provides that:
- Exemptions relating to therapeutic products are set out in the First Schedule;
- Exemptions relating to medical devices are set out in the Second Schedule;
- Exemptions relating to CTGT products are set out in the Third Schedule (added/updated by amendments effective 1 March 2021).
Section 3(1)–(3) effectively tells the practitioner where to look. The schedules are not merely descriptive; they are the legal source of the exemptions. In practice, counsel should read the schedule entries alongside the relevant provisions of the Health Products Act and the applicable regulations to understand the precise regulatory obligations that are waived.
Section 4 (Revocation) revokes two earlier medical device exemption orders: Health Products (Medical Devices) (Exemption) Order 2012 and Health Products (Medical Devices) (Exemption No. 2) Order 2012. This is significant for historical compliance analysis and for ensuring that stakeholders do not rely on revoked instruments. It also indicates that the 2016 Order consolidated or replaced earlier exemption frameworks for medical devices, at least as far as those exemption orders covered.
Schedules (First, Second, Third) are the substantive heart of the Exemptions Order. Although the extract provided does not reproduce the schedule text, the structure signals that each schedule lists specific exemptions for the relevant product category. For practitioners, the key legal task is to identify:
- the type of product (therapeutic, medical device, CTGT);
- the activity being exempted (e.g., importation, supply, registration/authorisation, or other regulatory steps); and
- any conditions attached to the exemption (for example, limitations on use, distribution channels, or documentation requirements).
Because exemptions are typically construed strictly, reliance should be supported by a careful reading of the schedule entry and any cross-referenced definitions or regulatory provisions.
How Is This Legislation Structured?
The Exemptions Order is structured as a short, enabling instrument with four sections and three schedules:
- Section 1: Citation and commencement.
- Section 2: Definitions (including product categories and referenced regulations).
- Section 3: Exemptions are allocated to schedules by product category.
- Section 4: Revocation of earlier medical device exemption orders.
- First Schedule: Exemptions relating to therapeutic products.
- Second Schedule: Exemptions relating to medical devices.
- Third Schedule: Exemptions relating to CTGT products.
From a legal research perspective, this structure means that the “action” is in the schedules. The sections provide the framework and definitions, while the schedules provide the operative exemption lists.
Who Does This Legislation Apply To?
The Exemptions Order applies to persons and entities whose activities fall within Singapore’s regulatory oversight under the Health Products Act—particularly those dealing with therapeutic products, medical devices, and CTGT products. This typically includes manufacturers, importers, distributors, sponsors, and other regulated stakeholders who would otherwise need to comply with requirements under the Health Products Act and its subsidiary regulations.
However, the Order’s exemptions are not blanket. They apply only to the extent that a stakeholder’s product and activity fit within the specific exemption categories in the relevant schedule. Accordingly, the practical applicability depends on (i) correct product classification under the Health Products Act’s categorisation scheme and (ii) whether the stakeholder’s conduct matches the scope of the exemption entry.
Why Is This Legislation Important?
The Exemptions Order is important because it determines when regulatory burdens do not apply. In the health products context, regulatory obligations can be substantial—covering authorisation, registration, compliance systems, and oversight mechanisms. Exemptions can therefore materially affect commercial timelines, cost structures, and risk management strategies.
For practitioners, the Order is also significant for enforcement and compliance. If a party incorrectly claims an exemption, it may be treated as having failed to comply with the underlying regulatory requirements. Because exemptions are generally interpreted narrowly, counsel should treat the schedule entries as the definitive legal boundaries and should document the basis for exemption reliance (including product classification and factual alignment with any conditions).
Finally, the inclusion of CTGT product exemptions (via amendments effective 1 March 2021) reflects the evolution of Singapore’s regulatory framework to cover advanced therapies. This makes the Exemptions Order a living compliance instrument: stakeholders in the CTGT space should monitor amendments and ensure that their exemption positions remain valid under the current version as at the relevant date.
Related Legislation
- Health Products Act (Cap. 122D) — authorising framework; product categorisation; regulatory obligations and enforcement.
- Health Products (Therapeutic Products) Regulations 2016 (G.N. No. S 329/2016) — referenced in the Exemptions Order’s definitions.
- Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (G.N. No. S 104/2021) — referenced in the Exemptions Order’s definitions.
- Health Products (Medical Devices) (Exemption) Order 2012 (G.N. No. S 170/2012) — revoked by Section 4.
- Health Products (Medical Devices) (Exemption No. 2) Order 2012 (G.N. No. S 427/2012) — revoked by Section 4.
Source Documents
This article provides an overview of the Health Products (Exemptions) Order 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.